ACER - Acer Therapeutics Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
3.7550
-0.3650 (-8.86%)
As of 1:19PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close4.1200
Open4.0600
Bid3.7900 x 1100
Ask3.8000 x 2200
Day's Range3.7111 - 4.0600
52 Week Range3.7111 - 34.1000
Volume1,057,853
Avg. Volume161,170
Market Cap37.878M
Beta (3Y Monthly)3.08
PE Ratio (TTM)N/A
EPS (TTM)-2.7460
Earnings DateNov 12, 2018 - Nov 16, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est51.40
Trade prices are not sourced from all markets
  • Acer Shares Down on FDA's CRL for Genetic Disorder Treatment
    Zacks5 hours ago

    Acer Shares Down on FDA's CRL for Genetic Disorder Treatment

    Acer Therapeutics Inc. (ACER) receives a Complete Response Letter from the FDA regarding its new drug application for Edsivo for the treatment of vascular Ehlers-Danlos syndrome.

  • Benzinga6 hours ago

    The Daily Biotech Pulse: Decision Day For Regeneron-Sanofi, Vermillion Offering, PDL BioPharma CFO to Depart

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 25) ArQule, Inc. (NASDAQ: ARQL ) Zai Lab Ltd (NASDAQ: ZLAB ...

  • TheStreet.com21 hours ago

    Acer Plummets After FDA Declines to OK Rare Genetic Disorder Treatment

    plummeted by nearly 80% toward a record low after the pharmaceutical company said the Food and Drug Administration declined to approve its treatment for a genetic disorder that can cause blood vessels to fatally rupture. The treatment, Edsivo (celiprolol), was developed to treat patients with vascular Ehlers-Danlos syndrome (vEDS), a rare but severe hereditary disorder of the connective tissue. In its response letter, the FDA has asked the company to conduct an "adequate and well-controlled trial" to determine whether Edsivo reduces the risk of clinical events in patients with vEDS.

  • ACCESSWIRE22 hours ago

    Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Acer Therapeutics Inc. (ACER)

    NEW YORK, NY / ACCESSWIRE / June 25, 2019 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Acer Therapeutics Inc.("Acer" or the "Company") ...

  • GlobeNewswireyesterday

    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Acer Therapeutics Inc. - ACER

    Pomerantz LLP is investigating claims on behalf of investors of Acer Therapeutics Inc. (“Acer” or the “Company”) (NASDAQ: ACER).  Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. On June 25, 2019, Acer disclosed receipt of a Complete Response Letter (“CRL”) from the U.S. Food and Drug Administration (“FDA”) regarding its marketing application for EDSIVO (celiprolol) for the treatment of vascular Ehlers-Danlos syndrome (“vEDS”).  Acer advised investors that “[t]he CRL states that it will be necessary to conduct an adequate and well-controlled trial to determine whether celiprolol reduces the risk of clinical events in patients with vEDS” and that “Acer plans to request a meeting to discuss the FDA’s response.”  On this news, Acer’s stock price fell sharply during intraday trading on June 25, 2019.

  • Acer Therapeutics stock plummets 80 percent on FDA rejection
    American City Business Journalsyesterday

    Acer Therapeutics stock plummets 80 percent on FDA rejection

    The FDA rejected Acer's application this week, tasking the company with conducting new trials of the drug, called edsivo, before re-submitting it approval.

  • MarketWatchyesterday

    Acer Therapeutics stock loses over 80% of its value after receiving CRL from FDA for Edsivo

    Acer Therapeutics Inc. said Tuesday it received a complete response letter (CRL) from the U.S. Food and Drug Administration regarding its new drug application (NDA) for Edsivo, a treatment of vascular Ehlers-Danlos syndrome (vEDS). After resuming trade following a halt for news, the stock plummeted 81% toward a record low in premarket trading. Volume of over 140,000 shares was already more than the full-day average of about 97,000 shares. The CRL says Acer will have to conduct an adequate and well-controlled trial to determine whether Edsivo (celiprolol) lowers the risk of clinical events in patients with vEDS. "We remain committed to working closely with the FDA to fully understand its response," Acer Chief Executive Chris Schelling said in a statement. "We expect to respond to the FDA in the third quarter of this year." The stock has lost 4.2% year to date through Monday, while the Dow Jones Industrial Average has gained 14.6%.

  • Reutersyesterday

    FDA declines to approve Acer Therapeutics' treatment for rare genetic disorder

    The treatment, Edsivo, aims to treat vascular Ehlers-Danlos syndrome (vEDS)- the most severe type of a hereditary disorder of the connective tissue. FDA, in its complete response letter, has asked Acer to conduct further trials to determine the efficiency of Edsivo in treating patients with vEDS, Acer said. "We expect to respond to the FDA in the third quarter of this year," Acer Chief Executive Officer Chris Schelling said.

  • Reutersyesterday

    UPDATE 2-FDA declines to approve Acer Therapeutics' rare genetic disorder treatment

    Acer Therapeutics Inc said on Tuesday the U.S. Food and Drug Administration declined to approve its treatment for a severe, rare genetic disorder that can cause blood vessels to fatally rupture, sending its shares plunging as much as 78%. The treatment, Edsivo, aims to treat vascular Ehlers-Danlos syndrome (vEDS)- the most severe type of a hereditary disorder of the connective tissue. The agency, in its complete response letter, has asked Acer to conduct a clinical trial to determine the efficiency of Edsivo in treating patients with vEDS, Acer said.

  • GlobeNewswireyesterday

    Acer Therapeutics Receives Complete Response Letter from U.S. FDA for use of EDSIVO™ (celiprolol) in vEDS Patients

    Acer Therapeutics Inc. (ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for EDSIVO™ for the treatment of vascular Ehlers-Danlos syndrome (vEDS). Acer plans to request a meeting to discuss the FDA’s response.

  • Benzinga16 days ago

    Wedbush Remains Bullish On Acer Therapeutics, Says Edsivo Review Appears On Track

    The PDUFA date for a potential FDA approval of Edsivo for the treatment of Vascular Ehlers-Danlos Syndrome (vEDS) patients is scheduled for June 25, Chico said in the note. Regarding investor concern around whether the data supporting Edsivo’s filing was too limited for an FDA approval, Chico said that it is consistent with the filings of recently approved orphan indications.

  • GlobeNewswire26 days ago

    Acer Therapeutics Announces Poster Presentation at Society for Vascular Medicine Annual Meeting

    Acer Therapeutics Inc. (ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced the presentation and publication of results from its Pilot Study to Evaluate Effect of Antihypertensive Therapy on the Rates of Clinical Events in Patients with Vascular Ehlers-Danlos Syndrome (vEDS).

  • PR Newswirelast month

    Wedbush Securities Senior Vice President of Equity Research Laura Chico, Ph.D. Initiates Coverage on Six Stocks in the Healthcare and BioTech Space - ACER, ACOR, ALNX, BIIB, DOVA and SAGE

    LOS ANGELES , May 23, 2019 /PRNewswire/ -- Wedbush Securities is pleased to announce that Senior Vice President of Equity Research, Laura Chico , Ph.D., initiates coverage on six stocks in the Healthcare ...

  • GlobeNewswirelast month

    Acer Therapeutics to Present at Upcoming Investor Conferences

    NEWTON, Mass., May 23, 2019 -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for.

  • GlobeNewswirelast month

    Acer Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update

    NEWTON, Mass., May 14, 2019 -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for.

  • GlobeNewswire2 months ago

    Acer Therapeutics to Present at UBS Global Healthcare Conference

    NEWTON, Mass., May 07, 2019 -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for.

  • GlobeNewswire2 months ago

    Acer Therapeutics Announces Publication of Vascular Ehlers-Danlos Syndrome (vEDS) Patient Registry Data

    Acer Therapeutics Inc. (ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with critical unmet medical needs, today announced the publication of long-term data from a cohort of COL3A1-positive vEDS patients in the Journal of the American College of Cardiology (JACC). The publication, entitled “Vascular Ehlers-Danlos Syndrome: Long-Term Observational Study,” was authored by Michael Frank, MD, Xavier Jeunemaitre, MD, PhD, and Pierre Boutouyrie, MD, PhD, et al.

  • Introducing Acer Therapeutics (NASDAQ:ACER), A Stock That Climbed 27% In The Last Year
    Simply Wall St.3 months ago

    Introducing Acer Therapeutics (NASDAQ:ACER), A Stock That Climbed 27% In The Last Year

    Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! If you want to compound wealth in the stock market, you can do so by buying an index fund. But you can significantl...

  • GlobeNewswire3 months ago

    Acer Therapeutics to Participate in Upcoming Investor Conferences

    NEWTON, Mass., March 13, 2019 -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for.

  • GlobeNewswire4 months ago

    Acer Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update

    NEWTON, Mass., March 07, 2019 -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for.

  • GlobeNewswire6 months ago

    Acer Therapeutics Announces In-license of Osanetant from Sanofi

    Acer Therapeutics Inc. (ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with critical unmet medical need, today announced that it has entered into an exclusive license agreement with Sanofi to acquire worldwide rights to osanetant, a clinical-stage, selective, non-peptide tachykinin NK3 receptor antagonist. Acer plans to initially pursue development of osanetant as a potential treatment for certain neuroendocrine-related disorders.

  • Is This Biotech Stock Turning A Corner? Acer Pops On FDA Acceptance
    Investor's Business Daily6 months ago

    Is This Biotech Stock Turning A Corner? Acer Pops On FDA Acceptance

    Acer Therapeutics jumped Wednesday after the FDA accepted its application for a drug to treat a connective-tissue disorder. The drug, Edsivo, would treat patients with a genetic mutation.

  • GlobeNewswire6 months ago

    Acer Therapeutics Announces FDA Acceptance of NDA and Priority Review for EDSIVO™ for the Treatment of vEDS

    Acer Therapeutics Inc. (ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and ultra-rare diseases with critical unmet medical need, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review Acer’s New Drug Application (NDA) for EDSIVO™ for the treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed type III collagen (COL3A1) mutation. The FDA also granted a priority review of the NDA and assigned a Prescription Drug User Fee Act (PDUFA) target action date of June 25, 2019.

  • Opexa Therapeutics Enters Oversold Territory
    Zacks6 months ago

    Opexa Therapeutics Enters Oversold Territory

    Opexa Therapeutics has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

  • GlobeNewswire6 months ago

    Acer Therapeutics Appoints Salma Jutt as Chief Commercial Officer

    Acer Therapeutics Inc. (ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and ultra-rare diseases with critical unmet medical need, today announced that it has appointed Salma Jutt as Chief Commercial Officer. If EDSIVO™ is approved by the FDA for the treatment of vascular Ehlers-Danlos syndrome (vEDS), Ms. Jutt will lead its launch and commercialization.